Catalyst Pharmaceuticals (CPRX) Set to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Catalyst Pharmaceuticals has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The company had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $14.72 on Monday. The stock has a market cap of $1.74 billion, a P/E ratio of 24.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.89. Catalyst Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $17.76. The stock has a 50 day simple moving average of $15.65 and a two-hundred day simple moving average of $14.71.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Bank of America assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a “buy” rating and a $23.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $34.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $26.43.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.